Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DT-202
- Development stage
- Preclinical
- Lead developer
- Dystrogen Therapeutics
- Modality
- Cell Therapies
01
Overview
DT-202 is an investigational cell therapy developed by Dystrogen Therapeutics for the treatment of age-related muscle loss. It is based on the company's proprietary chimeric cell platform, which involves the creation of chimeric cells designed to regenerate or support muscle tissue. While the platform's lead candidate, DT-DEC01, is a Dystrophin Expressing Chimeric (DEC) cell therapy for Duchenne Muscular Dystrophy, DT-202 is a distinct discovery-stage program specifically targeting muscle loss associated with aging. The therapy aims to leverage the regenerative potential of chimeric cell populations to address muscle wasting in older populations.
Beyond the preview
Go deeper on DT-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DT-202.